We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01873326
Recruitment Status : Active, not recruiting
First Posted : June 10, 2013
Last Update Posted : September 29, 2017
University of Southern California
Mayo Clinic
University of Pittsburgh
University of North Carolina
University of Chicago
Stanford University
University of Texas Southwestern Medical Center
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : June 2018
  Estimated Study Completion Date : June 2018